Home/Filings/4/0000950170-24-046871
4//SEC Filing

Rangwala Reshma 4

Accession 0000950170-24-046871

CIK 0001503802other

Filed

Apr 22, 8:00 PM ET

Accepted

Apr 23, 4:02 PM ET

Size

4.9 KB

Accession

0000950170-24-046871

Insider Transaction Report

Form 4
Period: 2024-04-22
Rangwala Reshma
EVP & Chief Medical Officer
Transactions
  • Sale

    Common Stock

    2024-04-22$1.17/sh6,789$7,943342,931 total
Footnotes (1)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001825322

Filing Metadata

Form type
4
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 4:02 PM ET
Size
4.9 KB